Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
作者信息
Fiorentino B, Di Stefano P, Giuliani C, Amatetti C, Tinari N, Natoli C, Garufi C, Iacobelli S
机构信息
Cattedra di Oncologia Medica, Chieti, Italy.
出版信息
Br J Cancer. 1992 Nov;66(5):981-3. doi: 10.1038/bjc.1992.396.
Abstract
摘要
相似文献
1
Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
Br J Cancer. 1992 Nov;66(5):981-3. doi: 10.1038/bjc.1992.396.
2
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
Br J Cancer. 1991 Feb;63(2):287-92. doi: 10.1038/bjc.1991.67.
3
Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Eur J Surg Oncol. 1993 Jun;19(3):265-72.
4
Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
Cancer Biother. 1994 Summer;9(2):103-11. doi: 10.1089/cbr.1994.9.103.
5
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
J Natl Cancer Inst. 1992 Jun 17;84(12):929-37. doi: 10.1093/jnci/84.12.929.
6
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
J Clin Oncol. 1996 Aug;14(8):2234-41. doi: 10.1200/JCO.1996.14.8.2234.
7
8
Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.
Eur J Cancer. 1991;27(8):1009-14. doi: 10.1016/0277-5379(91)90270-n.
9
Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
J Clin Oncol. 2004 Jul 15;22(14):2891-900. doi: 10.1200/JCO.2004.10.045.
10
Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Tumour Biol. 1993;14(6):354-9. doi: 10.1159/000217850.
本文引用的文献
1
Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Important Adv Oncol. 1986:55-91.
2
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
Ann Intern Med. 1988 Jun;108(6):853-64. doi: 10.7326/0003-4819-108-6-853.
3
Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.
J Natl Cancer Inst. 1988 Nov 2;80(17):1393-7. doi: 10.1093/jnci/80.17.1393.
4
5
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
J Biol Response Mod. 1988 Apr;7(2):123-39.
6
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
Cancer Res. 1988 May 1;48(9):2561-7.
7
8
9
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.
J Clin Oncol. 1989 Nov;7(11):1726-32. doi: 10.1200/JCO.1989.7.11.1726.
10
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
J Clin Oncol. 1989 Dec;7(12):1863-74. doi: 10.1200/JCO.1989.7.12.1863.
Zotero 插件